Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis

Fig. 5

The effects of PTCI and TM on cell proliferation of breast cancer cell lines. MDA-MB-231 and SUM149 cells were subjected to the WST-1 assay as an index of proliferation. a Cells were treated with 10 μg/mL PTCI or 10 nM TM, for 24 h. b MDA-MB-231 cells were treated with 50 nM of the indicated TAFI variants, either with (Activated) or without (Non-Activated) prior treatment with thrombin-TM. Following the treatment, the WST-1 assay was conducted and metabolic activity of the cells assessed by measuring absorbance at 450 nm. The data represent the average cell number per field of view ± SEM from at least three independent experiments and are relative to the control in the absence of treatment

Back to article page